Correlation Between Apellis Pharmaceuticals and Ultragenyx

Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Ultragenyx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Ultragenyx into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Apellis Pharmaceuticals and Ultragenyx, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Ultragenyx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Ultragenyx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Ultragenyx.

Diversification Opportunities for Apellis Pharmaceuticals and Ultragenyx

0.46

Correlation Coefficient

Apellis Pharmaceuticals  Ultragenyx

Very weak diversification

The 3 months correlation between Apellis and Ultragenyx is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Ultragenyx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ultragenyx and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Ultragenyx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ultragenyx has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Ultragenyx go up and down completely randomly.

Pair Corralation between Apellis Pharmaceuticals and Ultragenyx

Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to generate 1.8 times more return on investment than Ultragenyx. However, Apellis Pharmaceuticals is 1.8 times more volatile than Ultragenyx. It trades about -0.04 of its potential returns per unit of risk. Ultragenyx is currently generating about -0.12 per unit of risk. If you would invest  3,890  in Apellis Pharmaceuticals on August 30, 2024 and sell it today you would lose (476.00) from holding Apellis Pharmaceuticals or give up 12.24% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.44%
Values	Daily Returns

Apellis Pharmaceuticals  vs.  Ultragenyx

Apellis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Ultragenyx

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Apellis Pharmaceuticals and Ultragenyx

The main advantage of trading using opposite Apellis Pharmaceuticals and Ultragenyx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Ultragenyx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ultragenyx will offset losses from the drop in Ultragenyx's long position.

The idea behind Apellis Pharmaceuticals and Ultragenyx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.